Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Janux Therapeutics, Inc. (JANX : NSDQ)
 
 • Company Description   
Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

Number of Employees: 81

 
 • Price / Volume Information   
Yesterday's Closing Price: $23.10 Daily Weekly Monthly
20 Day Moving Average: 631,110 shares
Shares Outstanding: 59.17 (millions)
Market Capitalization: $1,366.95 (millions)
Beta: 2.87
52 Week High: $71.71
52 Week Low: $22.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.64% -11.64%
12 Week -5.25% -22.70%
Year To Date -56.85% -59.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10955 Vista Sorrento Parkway Suite 200
-
San Diego,CA 92130
USA
ph: 858-751-4493
fax: -
investors@januxrx.com http://www.januxrx.com
 
 • General Corporate Information   
Officers
David Campbell - President and Chief Executive Officer
Ron Barrett - Chairperson of the Board of Directors
Vickie Capps - Director
Eric Dobmeier - Director
Sheila Gujrathi - Director

Peer Information
Janux Therapeutics, Inc. (CORR.)
Janux Therapeutics, Inc. (RSPI)
Janux Therapeutics, Inc. (CGXP)
Janux Therapeutics, Inc. (BGEN)
Janux Therapeutics, Inc. (GTBP)
Janux Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 47103J105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 59.17
Most Recent Split Date: (:1)
Beta: 2.87
Market Capitalization: $1,366.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.35
Price/Cash Flow: -
Price / Sales: 104.75
EPS Growth
vs. Year Ago Period: -26.67%
vs. Previous Quarter: -5.56%
Sales Growth
vs. Year Ago Period: -82.56%
vs. Previous Quarter: -95.07%
ROE
06/30/25 - -
03/31/25 - -9.29
12/31/24 - -9.22
ROA
06/30/25 - -
03/31/25 - -8.89
12/31/24 - -8.80
Current Ratio
06/30/25 - -
03/31/25 - 58.47
12/31/24 - 59.21
Quick Ratio
06/30/25 - -
03/31/25 - 58.47
12/31/24 - 59.21
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -832.71
12/31/24 - -651.62
Book Value
06/30/25 - -
03/31/25 - 17.11
12/31/24 - 19.49
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©